By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Acetylon Pharmaceuticals 

Boston  Massachusetts    U.S.A.
Phone: 617-435-2664 Fax: n/a




Company News
Acetylon Pharmaceuticals’s Oral Selective HDAC6 Inhibitor ACY-241 Enhances Anti-Tumor Activity Of Paclitaxel In Preclinical Solid Tumor Models 11/6/2015 8:10:15 AM
Acetylon Pharmaceuticals To Present At BioPharm America 2015 9/14/2015 3:10:26 PM
Acetylon Pharmaceuticals Presented Positive Preliminary Data From Phase 1b/2 Trial Of Ricolinostat In Combination With Pomalyst As Potential Oral Treatment For Patients With Multiple Myeloma 6/16/2015 11:47:06 AM
Acetylon Pharmaceuticals Presents Data On Synergistic Activity Of Selective HDAC6 Inhibition In Preclinical Models Of Multiple Myeloma And Mantle Cell Lymphoma At The AACR Annual Meeting 4/22/2015 8:44:05 AM
Acetylon Pharmaceuticals Announces Preclinical Anti-Cancer Activity Of Selective HDAC1/2 Inhibitors In Neuroblastoma And Acute Myeloid Leukemia 4/20/2015 1:05:32 PM
Acetylon Pharmaceuticals Presents At The Wells Fargo Celgene Partnership Forum 1/22/2015 10:55:50 AM
Acetylon Pharmaceuticals Presents Positive Preclinical Data On Selective HDAC1/2 Inhibition For The Treatment Of Sickle Cell Disease/?-Thalassemia 12/9/2014 1:48:47 PM
Acetylon Pharmaceuticals Announces Ricolinostat Continues To Demonstrate Clinically Meaningful And Durable Disease Response Rates In Phase 1b Combination Studies In Multiple Myeloma 12/9/2014 11:12:07 AM
Acetylon Pharmaceuticals Initiates Phase 2 Study Of Ricolinostat (ACY-1215) In Combination With Pomalyst® 12/4/2014 9:34:25 AM
Acetylon Pharmaceuticals’s Selective HDAC Inhibitors To Be Featured In Multiple Presentations Of Positive Clinical And Preclinical Data At The 56th American Society of Hematology Annual Meeting And Exposition 12/1/2014 2:45:37 PM